The review discusses MCP’s ability to control metastatic melanoma, as well as prostate, breast and colon cancers. These outcomes have been confirmed in multiple published studies, which have also shown MCP’s ability to suppress angiogenesis (new blood vessel growth to tumors). Blocking angiogenesis is a key factor in preventing cancer metastasis.

MCP has also been shown to induce apoptosis in cancer cells. Apoptosis, known as programmed cell death, is suppressed in tumors, allowing them to grow uncontrollably.  Numerous studies show MCP supports apoptosis in cancer, including a 2010 study from Columbia University which found that MCP induced apoptosis in both androgen dependent and androgen independent prostate cancer cells. This is particularly significant because androgen independent prostate cancer is a highly aggressive, difficult-to-treat cancer.

Other important findings demonstrate MCP’s abilities to make chemotherapy more effective. Co-administering MCP with cisplatin, etoposide or doxorubicin makes cancer cells more sensitive to these frontline treatments. MCP is also useful during radiation therapy, helping to protect organs from the damaging inflammatory effects of radiation.